PATENT Case No. 2075

JNITED STATES PATENT AND TRADEMARK OFFICE

Serial No. 09/973,853

Filed: October 10, 2001

For: AZA-AND POLYAZA-NAPHTHALENYL

nthony et al.

CARBOXAMIDES USEFUL AS INTEGRASE

INHIBITORS

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Art Unit: 1624

Examiner: Coleman, Brenda I

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir: 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement

is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention.

In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined

in 37 C.F.R. 1.56(b).

- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- Pursuant to the waiver by the Office of the requirement under 37 CFR 1.98 (a)(2)(i) dated July 11, 2003, if the filing date of this application is after June 30, 2003, copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

05/13/2004 SDIRETAI 00000016 132755 160.00 DA 01 FC:1806

COMMISSIONER FOR PATENTS, P.O. BOX 1450,

Computer generated form "IDS Letter" (IDS Folder), Merck & Co., Inc., 08/11/2003

Approved for use through 07/31/2006. OMB 0651-0032 U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE SUBSTITUTE for PTO/SB/17(10-03)"FEE TRANSMITTAL for FY 2003"

Complete if Known FEE TRANSMITTAL 09/973,853 Application Number Filing Date October 10, 2001 First Named Inventor Anthony et al. fees are subject to annual revision. Examiner Name Coleman, Brenda L. Group Art Unit 1624 TOTAL AMOUNT OF PAYMENT 20757Y Attorney Docket Number

	М	ETHOD OF PAYMENT	FEE CALCULATION (continued)			
×	Deposit Acc	ount	3. ADDITIONAL FEES			
Deposit Account 13-2755			Large Entity			
Num Den	nber osit Account		Fee Code	Fee (\$)	Fee Description	Fee Paid
Nam		Merck & Co., Inc.	1051	130	Surcharge - late filing fee or oath	
The	Director is a	uthorized to:	1812	2,520	For filing a request for ex parte	
X	Charge fee(s)	indicated below X Credit any overpayments	10.2	2,520	reexamination	
X	Charge any a	dditional fee(s) during the pendency of this	1251	110	Extension for reply within first month	
	application		1252	420	Extension for reply within second month	:
		FEE CALCULATION	1253	950	Extension for reply within third month	
1. BAS	IC FILIN	G FEE	1254	1,480	Extension for reply within fourth month	
Large	Entity	Fee Description Fee Paid	1255	2,010	Extension for reply within fifth month	
Fee Code	Fee (\$)	ree Description ree ratu	1401	330	Notice of Appeal	
1001	770	Utility filing fee	1402	330	Filing a brief in support of an appeal	- 1
1002	340	Design filing fee	1403	290	Request for oral hearing	
1004	770	Reissue filing fee	1452	110	Petition to revive - unavoidable	
1005	160	Provisional filing fee	1453	1,330	Petition to revive - unintentional	
			1501	1,330	Utility issue fee (or reissue)	
		SUBTOTAL(1) \$0	1502	480	Design issue fee	
2. EXT	RA CLAI		1460	130	Petitions to the Commissioner	
		Extra Fee from Fee Paid below	1807	50	Processing fee under 37 CFR 1.17(q)	
Total Cla	aims	- 20 ** = 0 x \$18 = 0	1806	180	Submission of Information Disclosure	180
Independ Claim		- 3 ** = 0 x \$86 = 0			Statement	180
	Dependent	Claims \$290 =	8021	40	Recording each patent assignment per property (times number of properties)	
**or num	ber previousl	y paid, if greater; For Reissues, see below	1809	770	Filing a submission after final rejection	
Large Fee	Entity Fee	Fee Description	1005	,,,	(37 CFR 1.129(a))	
Code 1202	(\$)	Claims in excess of 20	1810	770	For each additional invention to be examined (37 CFR 1.129(b))	
1201	86	Independent claims in excess of 3	1801	770	Request for Continued Examination	
1203	290	Multiple dependent claim, if not paid			(RCE)	
1204 86 **Reissue independent claims over original patent		Other fe	e (specify)) 		
1205	18	**Reissue claims in excess of 20 and over original	Other fe	e (specify)		
		SUBTOTAL(2) \$0			SUBTOTAL(3)	\$180

	SUBMITTED BY	Comp	lete (if applicable)		
Typed or Printed Name	Kenneth R. Walton	•		Reg. Number	32,951
Signature	Kuneth R. Watter	Date	05/11/2004	Deposit Account User ID	

PATENT Case No. 2	20757Y
-------------------	--------

INFORMATION DISCLOSURE STATEMENT

by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED APPLICATION				
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE			
If this is inconvenient, additional copies will be submitted upon reques	st.	I			
6. In accordance with 37 C.F.R. 1.97, (check one)					
the attached information is filed within three months of the filing da	ate of the captioned case.				
the attached information is filed more than three months after the Office Action on the merits.	filing date but prior to the r	nailing of a first			
the attached information is being filed more than three months afto Office Action on the merits, but before the mailing date of a Final authorization is therefore given to charge Deposit Account No. 13-1.17(p).	Action or Notice of Allowar	ce. The enclosed			
the undersigned certifies that each item of information contained i cited in any communication from a foreign patent office in a count					

the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37

Respectfully submitted,

By: Kenneth R. Walton

Attorney For Applicant(s)

Reg. No. 32,951

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-3462

Date: May 11, 2004

months prior to the filing of this Statement.

C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Sut	bstitute for form 1449A/PTO		-	COMPLETE IF KNOWN			
I	NFORMATION	DIS	CLOSURE	Application Number	09/973,853		
C.	TATEMENT BY	7 A TO	DI ICANIT	Filing Date	October 10, 2001		
3	/ 9	AF	PLICANI	First Named Inventor	Anthony et al.		
	MAY 1 1 2004	<i>y</i> /	,	Group Art Unit	1624		
	RADEMARK	s as n	necessary)	Examiner Name	Coleman, Brenda L.		
Sheet	l	of	2	Attorney Docket Number	20757Y		

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (f known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
	A.	5,753,666		Beasley et al.	05/19/1998			
	B.	3,945,995		Yamada et al.	03/23/1976			
			-					
			-					
			-					

			FORE	IGN PATEN	T DOCUMENTS	
Examiner Initials*	Cite No.	Foreign Patent Document Office Number		ent Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	C.	EPO	WO 99/15526	A2	Smithkline Beecham, PLC	04/01/1999
						
		-				
					Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003)

					Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE		
$\overline{}$	Substitute for form 1449B/PTO			COMPLETE IF KNOWN			
	INFORMATION	DIS	CLOSURE	Application Number	09/973,853		
	STATEMENTBY	7 A 1D	DI ICANT	Filing Date	October 10, 2001		
	STATEMENT D	I AL	ILICANI	First Named Inventor	Anthony et al.		
ļ	MAY 1 1 2004			Group Art Unit	1624		
(use as many speets as necessary)				Examiner Name	Coleman, Brenda L.		
Shee	RADEMARK	of	2	Attorney Docket Number	20757Y		

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
	D.	J. Bedard et al., "Antiviral Properties of a Series of 1,6-Naphthyridine and 7,8-Dihydroisoquinoline Derivatives Exhibiting Potent Activity Against Human Cytomegalovirus", 2000, Vol. 44, Antimicrobial Agents and Chemotherapy.					
	. —						
		•					

	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.